



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

3

Complete if Known

| | |
|------------------------|----------------|
| Application Number | 10/735,577 |
| Filing Date | 12/12/2003 |
| First Named Inventor | WAISMAN, David |
| Art Unit | |
| Examiner Name | |
| Attorney Docket Number | ME03-009 |

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| TV | A | WO 02 44328 | 06-06-2002 | Kwon; Waisman | , | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

**Examiner
Signature**

Date
Considered

9 | 22 | 05

²EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ³Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

Application Number

10/735,577

Filing Date

12/12/2003

First Named Inventor

WAISMAN, David

Art Unit

Examiner Name

Attorney Docket Number

ME03-009

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | |
| TW | B | CAPLAN JF, NR FILIPENKO, SL FITZPATRICK AND DM WAISMAN. Regulation of Annexin A2 by Reversible Glutathionylation. Journal of Biological Chemistry. 279(9): 7740-7750, 2004. USA | | T ² |
| | C | CHOI KS, FOGG DK, YOON CS, WAISMAN DM. p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. FASEB J. Feb;17(2):235-46, 2003. USA | | |
| | D | CHOI K-S, ET AL. Regulation of Plasmin-Dependent Fibrin Clot Lysis by Annexin II Heterotetramer. Journal of Biological Chemistry. 276(27):25212-25221, 2001. USA | | |
| | E | FILIPENKO NR, J GHUMAN, G KASSAM, H-M KANG, SL FITZPATRICK AND DM WAISMAN. Annexin II Tetramer Inhibits Plasmin-Dependent Fibrinolysis. Biochemistry. 37:648-655, 1998. USA | | |
| | F | FILIPENKO NR, TJ MACLEOD, C-S YOON AND DM WAISMAN. Annexin A2 is a Novel RNA Binding Protein. Journal of Biological Chemistry. Published online Dec 11 2003. USA | | |
| | G | FILIPENKO NR AND DM WAISMAN. The C Terminus of Annexin II Mediates Binding to F-Actin. Journal of Biological Chemistry. 276(7): 5310-5315, 2001. USA | | |
| | H | FILIPENKO NR AND DM WAISMAN. Characterization of Ca ²⁺ -binding Sites of Annexin II Tetramer. Journal of Biological Chemistry. 275(49):38877-38884, 2000. USA | | |
| | I | FITZPATRICK SL, G KASSAM A MANRO, CE BRAAT, P LOUIS AND DM WAISMAN. Fucoidan Dependent Conformational Changes in Annexin II Tetramer. Biochemistry. 39:2140-2148, 2000. USA | | |
| | J | FOGG DK, ET AL. The p11 Subunit of Annexin II Heterotetramer is Regulated by Basic Carboxypeptidase. Biochemistry. 41:4953-4961, 2002. USA | | |
| | K | KANG H-M, ET AL. Characterization of Human Recombinant Annexin II Tetramer Purified from Bacteria: Role of N-Terminal Acetylation. Biochemistry. 37:2041-2050, 1997. USA | | |

Examiner Signature

Draw 01/01/2005

Date Considered

9/22/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

3

Application Number

10/735,577

Filing Date

12/12/2003

First Named Inventor

WAISMAN, David

Art Unit

Examiner Name

Attorney Docket Number

ME03-009

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| TV | L | KASSAM G, KWON, YOUNG, GRAHAM, YOUNG, GLUCK & WAISMAN. Purification and Characterization of A61. Journal of Biological Chemistry. 276(23):8924-8933, 2001. USA | |
| | M | KASSAM G, ET AL. The Role of Annexin II Tetramer in the Activation of Plasminogen. Journal of Biological Chemistry. 273(8): 4790-4799, 1998. USA | |
| | N | KASSAM G, ET AL. The p11 Subunit of the Annexin II Tetramer Plays a Key role in the Stimulation of t-Pa-Dependent Plasminogen Activation. Biochemistry. 37:16958-16966, 1998. US | |
| | O | KWON M, ET AL. Identification of Annexin II Heterotetramer as a Plasmin Reductase. Journal of Biological Chemistry. 277(13):10903-10911, 2002. USA | |
| | P | LAY AJ, JIANG, KISKER, FLYNN, UNDERWOOD, CONDRON & HOGG. Phosphoglycerate Kinase Acts in Tumour Angiogenesis as a Disulphide Reductase. Nature. 408:869-873, 2000. USA | |
| | Q | MACLEOD TJ, KWON, FILIPENKO & WAISMAN. Phospholipid associated Annexin AS-S100A10 Heterotetramer and Its Subunits. J Biol Chem. 278(28): 25577-25584, 2003. USA | |
| | R | STATHAKIS P, FITZGERALD, MATTHIAS, CHESTERMAN & HOGG. Generation of Angiostatin by Reduction and Proteolysis of Plasmin. J Biol Chem. 272(33):20641-29645, 1997. USA | |
| | S | ZHANG L, FOGG & WAISMAN. RNA Interference mediated Silencing of S100A10 Gene Attenuates Plasmin Generation & Invasiveness of Colo 222. J Biol Chem. 279(3):2053-2062, 2004. USA | |
| | T | Fitzpatrick et al., "Regulation of Plasmin Activity by Annexin II Tetramer," Biochemistry 39: 1021-1028, 2000. USA | |
| | | | |
| | | | |

Examiner Signature

Date Considered

9/22/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.